Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H24N2O |
Molecular Weight | 224.3425 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(NC1CCCCC1)NC2CCCCC2
InChI
InChIKey=ADFXKUOMJKEIND-UHFFFAOYSA-N
InChI=1S/C13H24N2O/c16-13(14-11-7-3-1-4-8-11)15-12-9-5-2-6-10-12/h11-12H,1-10H2,(H2,14,15,16)
Molecular Formula | C13H24N2O |
Molecular Weight | 224.3425 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/18312493Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24685540 | https://www.ncbi.nlm.nih.gov/pubmed/22489687
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18312493
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24685540 | https://www.ncbi.nlm.nih.gov/pubmed/22489687
1,3-Dicyclohexylurea (DCU) is a potent endogenous inhibitor of soluble epoxide hydrolase (sEH), that has been found in human serum. Soluble epoxide hydrolase has been implicated in cardiovascular disease and inflammation in mammals. Endogenously produced 1,3-dicyclohexylurea may have physiological significance via regulation of soluble epoxide hydrolase activity in vivo.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2409 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24685540 |
3.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Impurity profile study of repaglinide. | 2003 Jul 14 |
|
Structure-activity relationships of dinucleotides: Potent and selective agonists of P2Y receptors. | 2005 Jun |
|
14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha. | 2006 Jan |
|
Hydrolysis of cis- and trans-epoxyeicosatrienoic acids by rat red blood cells. | 2008 Jul |
|
Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. | 2008 May |
|
4-Methyl-3-(2-phenoxy-acet-yl)-5-phenyl-1,3,4-oxadiazinan-2-one. | 2009 Jun 6 |
|
2-(2-Chloro-3-quinol-yl)-3-phenyl-thia-zolidin-4-one. | 2009 Oct 17 |
|
Targeting the OB-Folds of Replication Protein A with Small Molecules. | 2010 Dec 6 |
|
Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugate. | 2010 Oct 21 |
|
Spacer/Linker based synthesis and biological evaluation of mutual prodrugs as antiinflammatory agents. | 2010 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18312493
From day 10 to day 14, rats were dosed orally with vehicle or 1,3-Dicyclohexylu at 30 mg/kg twice daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24685540
Cyano(6-methoxy-naphthalen-2-yl)methyl trans-[(3-phenyloxyran-2-yl)methyl] carbonate (CMNPC) is the substrate used for the fluorescent assay. The assay was carried out using a 96 well-plate format. There was a lane for background with PB buffer (100 mM sodium phosphate, pH = 7.4, 200 µL) and two lanes for positive control. Each inhibitor IC50¬ was determined based on triplicate experiments. Each inhibitor (the highest desired concentration, 2 µL, DMSO) was added to the PB buffer (100 mM sodium phosphate, pH = 7.4, 150 µL) at the first set of wells. A series of 2-fold dilution was applied from the first set till to the last set of wells. hSEH solution (25 nM, 100 mM sodium phosphate, pH = 7.4, 20 µL) was added and mixed for 30s. The inhibitor-enzyme mixtures were mixed and incubated at 30 ˚C for 5 min. CMNPC solution (33 µM, 100 mM sodium phosphate, pH = 7.4, 30 µL) was added and mixed. The enzyme activity was measured based on the fluorescence increase.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:50:35 GMT 2025
by
admin
on
Mon Mar 31 18:50:35 GMT 2025
|
Record UNII |
ZV7823VVIM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4277
Created by
admin on Mon Mar 31 18:50:35 GMT 2025 , Edited by admin on Mon Mar 31 18:50:35 GMT 2025
|
PRIMARY | |||
|
2387-23-7
Created by
admin on Mon Mar 31 18:50:35 GMT 2025 , Edited by admin on Mon Mar 31 18:50:35 GMT 2025
|
PRIMARY | |||
|
1369442
Created by
admin on Mon Mar 31 18:50:35 GMT 2025 , Edited by admin on Mon Mar 31 18:50:35 GMT 2025
|
PRIMARY | |||
|
DTXSID3062366
Created by
admin on Mon Mar 31 18:50:35 GMT 2025 , Edited by admin on Mon Mar 31 18:50:35 GMT 2025
|
PRIMARY | |||
|
Dicyclohexylurea
Created by
admin on Mon Mar 31 18:50:35 GMT 2025 , Edited by admin on Mon Mar 31 18:50:35 GMT 2025
|
PRIMARY | |||
|
219-213-7
Created by
admin on Mon Mar 31 18:50:35 GMT 2025 , Edited by admin on Mon Mar 31 18:50:35 GMT 2025
|
PRIMARY | |||
|
30023
Created by
admin on Mon Mar 31 18:50:35 GMT 2025 , Edited by admin on Mon Mar 31 18:50:35 GMT 2025
|
PRIMARY | |||
|
17013
Created by
admin on Mon Mar 31 18:50:35 GMT 2025 , Edited by admin on Mon Mar 31 18:50:35 GMT 2025
|
PRIMARY | |||
|
ZV7823VVIM
Created by
admin on Mon Mar 31 18:50:35 GMT 2025 , Edited by admin on Mon Mar 31 18:50:35 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
No more than one such impurity (carmustine related compound A, lomustine related compound B, or lomustine related compound C) is greater than 0.2%.
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|